REG - Argent Biopharma Ltd - Change of OTCQB Company Code

Argent BioPharmaAnnouncement

23/05/2024 08:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240523:nRSW6271Pa&default-theme=true

RNS Number : 6271P  Argent Biopharma Limited  23 May 2024

 

23 May 2024

 

Argent BioPharma Ltd.

 

Change of OTCQB Company Code

 

Argent BioPharma Ltd. (Argent BioPharma or the Company) advises that as of 20
May 2024, the Company's new trading code on the OTCQB changed to RGTLF.

 

This adjustment aligns with the Company's recent change in registered name
with the Australian Securities and Investments Commission (ASIC) and trading
code on the ASX and LSE.

 

 

-Ends-

 

 

Authorised for release by the board of directors, for further information
please contact:

 

 Argent BioPharma                                             Argent BioPharma

 Roby Zomer                                                   Rowan Harland

 CEO & Managing Director                                      Company Secretary

 +61 8 6382 3390                                              +61 8 6382 3390

 info@argentbiopharma.co (mailto:info@argentbiopharma.co) m   info@argentbiopharma.co (mailto:info@argentbiopharma.co.uk) m

 UK IR/PR Advisers                                            UK Brokers

 IFC Advisory                                                 Oberon Capital

 Graham Herring / Tim Metcalfe / Zach Cohen                   Aimee McCusker / Adam Pollock

 +44 203 934 6630                                             +44 203 179 5300

 argentbiopharma@investor-focus.co.uk                         aimeemccusker@oberoninvestments.com
 (mailto:argentbiopharma@investor-focus.co.uk)                (mailto:aimeemccusker@oberoninvestments.com) adampollock@oberoninvestments.com
                                                              (mailto:adampollock@oberoninvestments.com)

 

 

 

About Argent BioPharma

 

Argent BioPharma purpose is to address unmet medical needs through the
pioneering integration of Nanotechnology and Multidisciplinary research
methods. Our approach heralds a transformative shift in healthcare, combining
the power of multi-targeted drug therapies with precision nanoscale delivery
to enhance treatment efficacy while reducing side effects. Central to our
ethos is making these innovative treatments accessible, ensuring they reach
those underserved by current medical solutions. As we endeavour to become
globally recognized in the life science industry, we are committed to bridging
healthcare gaps, redefining industry standards, and providing impactful
solutions and hope to communities worldwide.

 

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPUUWAUPCUQW